SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

SECTION 1. IDENTIFICATION

Product name: Pyrantel Pamoate / Ivermectin Formulation
Other means of identification: No data available

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue
          Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Specific target organ toxicity - single exposure (Oral): Category 1 (Central nervous system)
Specific target organ toxicity - repeated exposure (Oral): Category 1 (Central nervous system)

GHS label elements
Hazard pictograms: 🔴

Signal Word: Danger
Hazard Statements: H370 Causes damage to organs (Central nervous system) if swallowed.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Precautionary Statements: Prevention:
P260 Do not breathe dust, fume, gas, mist, vapors or spray.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:
P308 + P311 IF exposed or concerned: Call a doctor.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td>Mixture</td>
<td>4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
</tr>
<tr>
<td></td>
<td>Propylene glycol</td>
</tr>
<tr>
<td></td>
<td>Glycerine</td>
</tr>
<tr>
<td></td>
<td>Ivermectin</td>
</tr>
<tr>
<td></td>
<td>Ethanol</td>
</tr>
</tbody>
</table>

# Voluntarily-disclosed substance

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap as a precaution. Get medical attention if symptoms occur.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Causes damage to organs if swallowed. Causes damage to organs through prolonged or repeated exposure if swallowed.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

Version 5.3
Revision Date: 04/04/2023
SDS Number: 4892868-00016
Date of last issue: 02/07/2023
Date of first issue: 09/17/2019

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during fire fighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Sulfur oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

Version 5.3  Revision Date: 04/04/2023  SDS Number: 4892868-00016  Date of last issue: 02/07/2023  Date of first issue: 09/17/2019

Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling:
- Do not breathe dust, fume, gas, mist, vapors or spray.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store locked up.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Self-reactive substances and mixtures
  - Organic peroxides
  - Explosives
  - Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Propylene glycol</td>
<td>57-55-6</td>
<td>TWA (Vapour and aerosols)</td>
<td>50 ppm 155 mg/m³</td>
<td>CA ON OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (aerosol)</td>
<td>10 mg/m³</td>
<td>CA ON OEL</td>
</tr>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable mist)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (Mist)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Further information: Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>300 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Ethanol</td>
<td>64-17-5</td>
<td>TWA</td>
<td>1,000 ppm 1,880 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>1,000 ppm</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEV</td>
<td>1,000 ppm</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>1,000 ppm</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>
**Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

- **Respiratory protection:** If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter type: Combined particulates and organic vapor type
- **Hand protection**
  - Material: Chemical-resistant gloves
  - Remarks: Consider double gloving.
- **Eye protection**
  - Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- **Skin and body protection**
  - Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
- **Hygiene measures**
  - If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

- **Appearance:** paste
- **Color:** yellow
- **Odor:** No data available
- **Odor Threshold:** No data available
- **pH:** No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): No data available
Flammability (liquids): Not applicable
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: Not applicable
Relative vapor density: Not applicable
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility: No data available
Partition coefficient: n-octanol/water: Not applicable
Autoignition temperature: No data available
Decomposition temperature: No data available
Viscosity
Viscosity, kinematic: Not applicable
Explosive properties: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: Can react with strong oxidizing agents.
### Conditions to avoid
None known.

### Incompatible materials
Oxidizing agents

### Hazardous decomposition products
No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

- **Skin contact**
- **Ingestion**
- **Eye contact**

#### Acute toxicity
Not classified based on available information.

#### Product:

- **Acute oral toxicity**
  - Method: Calculation method
  - Acute toxicity estimate: > 2,000 mg/kg

- **Acute dermal toxicity**
  - Method: Calculation method
  - Acute toxicity estimate: > 2,000 mg/kg

#### Components:

- **4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):**
  - **Acute oral toxicity**
    - LD50 (Rat): > 24,000 mg/kg
    - LD50 (Mouse): > 24,000 mg/kg
    - LD50 (Dog): 2,000 mg/kg

- **Propylene glycol:**
  - **Acute oral toxicity**
    - LD50 (Rat): 22,000 mg/kg

- **Glycerine:**
  - **Acute oral toxicity**
    - LD50 (Rat): > 5,000 mg/kg

- **Ivermectin:**
  - **Acute oral toxicity**
    - LD50 (Rat): 50 mg/kg
    - LD50 (Mouse): 25 mg/kg
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity:  
LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity:  
LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

Ethanol:  
Acute oral toxicity:  
LD50 (Rat): > 5,000 mg/kg  
Method: OECD Test Guideline 401

Acute inhalation toxicity:  
LC50 (Rat): 124.7 mg/l  
Exposure time: 4 h  
Test atmosphere: vapor

Skin corrosion/irritation:  
Not classified based on available information.

Components:

Propylene glycol:  
Species: Rabbit  
Method: OECD Test Guideline 404  
Result: No skin irritation

Glycerine:  
Species: Rabbit  
Result: No skin irritation

Ivermectin:  
Species: Rabbit  
Result: No skin irritation

Ethanol:  
Species: Rabbit  
Method: OECD Test Guideline 404  
Result: No skin irritation

Serious eye damage/eye irritation:  
Not classified based on available information.
<table>
<thead>
<tr>
<th>Components:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Propylene glycol:</strong></td>
</tr>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Result: No eye irritation</td>
</tr>
<tr>
<td>Method: OECD Test Guideline 405</td>
</tr>
<tr>
<td><strong>Glycerine:</strong></td>
</tr>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Result: No eye irritation</td>
</tr>
<tr>
<td><strong>Ivermectin:</strong></td>
</tr>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Result: Mild eye irritation</td>
</tr>
<tr>
<td><strong>Ethanol:</strong></td>
</tr>
<tr>
<td>Species: Rabbit</td>
</tr>
<tr>
<td>Result: Irritation to eyes, reversing within 21 days</td>
</tr>
<tr>
<td>Method: OECD Test Guideline 405</td>
</tr>
</tbody>
</table>

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

<table>
<thead>
<tr>
<th>Components:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Propylene glycol:</strong></td>
</tr>
<tr>
<td>Test Type: Maximization Test</td>
</tr>
<tr>
<td>Routes of exposure: Skin contact</td>
</tr>
<tr>
<td>Species: Guinea pig</td>
</tr>
<tr>
<td>Result: negative</td>
</tr>
<tr>
<td><strong>Ivermectin:</strong></td>
</tr>
<tr>
<td>Routes of exposure: Dermal</td>
</tr>
<tr>
<td>Species: Humans</td>
</tr>
<tr>
<td>Result: Does not cause skin sensitization.</td>
</tr>
</tbody>
</table>

**Ethanol:**

| Test Type: Local lymph node assay (LLNA) |
| Routes of exposure: Skin contact |
| Species: Mouse |
| Result: negative |

**Germ cell mutagenicity**
Not classified based on available information.
Components:

4,4′-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

Propylene glycol:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative

Genotoxicity in vivo:
- Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative

Glycerine:

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: Chromosome aberration test in vitro
  - Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Result: negative

Ivermectin:

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
- Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
  - Test system: human diploid fibroblasts
  - Result: negative
- Test Type: Mouse Lymphoma
  - Result: negative

Ethanol:

Genotoxicity in vitro:
- Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
- Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo:
Test Type: Rodent dominant lethal test (germ cell) (in vivo)
Species: Mouse
Application Route: Ingestion
Result: equivocal

Carcinogenicity
Not classified based on available information.

Components:

Propylene glycol:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Glycerine:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Ivermectin:
Species: Rat
Application Route: Oral
NOAEL: 1.5 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Species: Mouse
Application Route: Oral
NOAEL: 2.0 mg/kg body weight
Result: negative
Remarks: Based on data from similar materials

Reproductive toxicity
Not classified based on available information.

Components:

4,4′-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Effects on fetal development:
Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility and early embryonic development were detected.

Propylene glycol:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Mouse
Application Route: Ingestion
Result: negative

Glycerine:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Ivermectin:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 0.6 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on fetal development: Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.
Remarks: The mechanism or mode of action may not be relevant in humans.

Test Type: Development
Species: Rabbit
Application Route: Oral
Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

Ethanol:
Effects on fertility
Test Type: Two-generation reproduction toxicity study
Species: Mouse
Application Route: Ingestion
Result: negative

STOT-single exposure
Causes damage to organs (Central nervous system) if swallowed.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT-repeated exposure
Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:
Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Species: Dog
NOAEL: 10 mg/kg
LOAEL: 30 mg/kg
Application Route: Ingestion
Exposure time: 3 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 19 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 30 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Propylene glycol:
Species: Rat, male
NOAEL: >= 1,700 mg/kg
Application Route: Ingestion
Exposure time: 2 y

Glycerine:
Species: Rat
NOAEL: 0.167 mg/l
LOAEL: 0.622 mg/l
Application Route: inhalation (dust/mist/fume)
Exposure time: 13 Weeks
Species: Rat
NOAEL: 8,000 - 10,000 mg/kg
Application Route: Ingestion
Exposure time: 2 y
Species: Rabbit
NOAEL: 5,040 mg/kg
Application Route: Skin contact
Exposure time: 45 Weeks

Ivermectin:
Species: Dog
NOAEL: 0.5 mg/kg
LOAEL: 1 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Target Organs: Central nervous system
Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia
Species: Monkey
NOAEL: 1.2 mg/kg
Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported
Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney
**Ethanol:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>1,280 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>3,156 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Ingestion</td>
</tr>
<tr>
<td>Exposure time</td>
<td>90 Days</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ingestion**

Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhea, Headache, Dizziness, Fever

**Ivermectin:**

**Skin contact**

Remarks: Can be absorbed through skin.

**Eye contact**

Remarks: May irritate eyes.

**Ingestion**

Remarks: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

---

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

4,4’-Methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ecotoxicology Assessment**

**Acute aquatic toxicity**

Toxic effects cannot be excluded

**Chronic aquatic toxicity**

Toxic effects cannot be excluded

**Propylene glycol:**

**Toxicity to fish**

LC50 (Oncorhynchus mykiss (rainbow trout)): 40,613 mg/l
Exposure time: 96 h

**Toxicity to daphnia and other aquatic invertebrates**

EC50 (Ceriodaphnia dubia (water flea)): 18,340 mg/l
Exposure time: 48 h

**Toxicity to algae/aquatic plants**

ErC50 (Skeletonema costatum (marine diatom)): 19,300 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**

NOEC (Ceriodaphnia dubia (water flea)): 13,020 mg/l
Exposure time: 7 d
Toxicity to microorganisms: NOEC (Pseudomonas putida): > 20,000 mg/l
Exposure time: 18 h

Glycerine:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1,955 mg/l
Exposure time: 48 h
Toxicity to microorganisms: NOEC (Pseudomonas putida): > 10,000 mg/l
Exposure time: 16 h
Method: DIN 38 412 Part 8

Ivermectin:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l
Exposure time: 96 h
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.000025 mg/l
Exposure time: 48 h
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Ethanol:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l
Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Ceriodaphnia (water flea)): > 1,000 mg/l
Exposure time: 48 h
Toxicity to algae/aquatic plants: ErC50 (Chlorella vulgaris (Fresh water algae)): 275 mg/l
Exposure time: 72 h
EC10 (Chlorella vulgaris (Fresh water algae)): 11.5 mg/l
Exposure time: 72 h
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 9.6 mg/l
Exposure time: 9 d
Toxicity to microorganisms: EC50 (Pseudomonas putida): 6,500 mg/l
Exposure time: 16 h
Persistence and degradability

Components:

Propylene glycol:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 98.3%
Exposure time: 28 d
Method: OECD Test Guideline 301F

Glycerine:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 92%
Exposure time: 30 d
Method: OECD Test Guideline 301D

Ivermectin:
Biodegradability: Result: Not readily biodegradable.
Biodegradation: 50%
Exposure time: 240 d

Ethanol:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 84%
Exposure time: 20 d

Bioaccumulative potential

Components:

Propylene glycol:
Partition coefficient: n-octanol/water: log Pow: -1.07

Glycerine:
Partition coefficient: n-octanol/water: log Pow: -1.75

Ivermectin:
Bioconcentration factor (BCF): 74

Ethanol:
Partition coefficient: n-octanol/water: log Pow: 3.22

Mobility in soil
No data available

Other adverse effects
No data available
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations. Do not dispose of waste into sewer.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3077
Proper shipping name: Environmentally hazardous substance, solid, n.o.s. (Ivermectin)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 956
Packing instruction (passenger aircraft): 956
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
UN number: UN 3077
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>AICS</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH</td>
<td>USA. ACGIH Threshold Limit Values (TLV)</td>
</tr>
<tr>
<td>CA AB OEL</td>
<td>Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)</td>
</tr>
<tr>
<td>CA BC OEL</td>
<td>Canada. British Columbia OEL</td>
</tr>
<tr>
<td>CA ON OEL</td>
<td>Ontario Table of Occupational Exposure Limits made under the Occupational Health and Safety Act.</td>
</tr>
<tr>
<td>CA QC OEL</td>
<td>Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants</td>
</tr>
<tr>
<td>ACGIH / STEL</td>
<td>Short-term exposure limit</td>
</tr>
<tr>
<td>CA AB OEL / TWA</td>
<td>8-hour Occupational exposure limit</td>
</tr>
<tr>
<td>CA BC OEL / TWA</td>
<td>8-hour time weighted average</td>
</tr>
<tr>
<td>CA BC OEL / STEL</td>
<td>short-term exposure limit</td>
</tr>
<tr>
<td>CA ON OEL / TWA</td>
<td>Time-Weighted Average Limit (TWA)</td>
</tr>
<tr>
<td>CA QC OEL / TWAEV</td>
<td>Time-weighted average exposure value</td>
</tr>
<tr>
<td>CA QC OEL / STEV</td>
<td>Short-term exposure value</td>
</tr>
</tbody>
</table>

AIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-
SAFETY DATA SHEET

Pyrantel Pamoate / Ivermectin Formulation

Version 5.3  Revision Date: 04/04/2023  SDS Number: 4892868-00016  Date of last issue: 02/07/2023
Date of first issue: 09/17/2019

Sources of key data used to compile the Material Safety Data Sheet:


Revision Date: 04/04/2023
Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8